ANDA 218182, held by Sun Pharma Canada. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 218182 (Lidocaine Hydrochloride), held by Sun Pharma Canada, was first approved by FDA on Dec 7, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS Lidocaine hydrochloride is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 7, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters